Injectable Formulations for Treatment of Inflammatory Bowel Disease
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 4 of these applications claim priority to application PCT/US2024/031569, filed May 30, 2024. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Patent lifetimeUsedRemaining | Confidence |
|---|---|---|---|---|---|---|
| US 12,304,956 | Dosing Regimen for Treating Inflammatory Bowel Disease In force · High confidence UsedRemaining | Paragon Therapeutics, Inc. | In force | High confidence | ||
| US 12,404,334 | Methods of Treating Gastrointestinal Inflammatory Disease In force · High confidence | Paragon Therapeutics, Inc. | In force | High confidence | ||
| US 12,703,749 | Method of Treating Inflammatory Bowel Disease In force · High confidence | Paragon Therapeutics, Inc. | In force | High confidence | ||
| US 12,760,108 | Injectable Formulations for Treatment of Inflammatory Bowel Disease In force · Medium confidence | Paragon Therapeutics, Inc. | In force | Medium confidence | ||
| Application 19/302,809 | Long Acting ALPHA4BETA7 Targeting Molecule Compositions for the Treatment Gastrointestinal Inflammatory Disease Pending Not granted | Paragon Therapeutics, Inc. | Pending | Not granted | ||
| Application 19/393,395 | Long Acting ALPHA4BETA7 Targeting Molecule Compositions for the Treatment Gastrointestinal Inflammatory Disease Pending Not granted | Paragon Therapeutics, Inc. | Pending | Not granted | ||
| Application 19/705,182 | Method of Treating Gastrointestinal Inflammatory Disease Pending Not granted | Paragon Therapeutics, Inc. | Pending | Not granted |
7 of 7 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
4 of these are in force and held by Paragon Therapeutics, Inc..
Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.